MEK-Inhibitor. To investigate whether the ERK1/2-pathway is involved in the mediation of dexmedetomidine's neuroprotective properties towards mechanically injured brain tissue we applied PD98059, inhibitor of ERK1/2's direct activator MEK1, in a 5 μM concentration along with 1 μM dexmedetomidine immediately after trauma. Here, n = 46 slices were subjected to the aforementioned conditions. As shown in Figure 5 trauma intensity was significantly higher in the inhibitor group than in the dexmedetomidine group (p = 0.033) but still appreciably lower than in the positive control group (p ≤ 0.001).
Schoeler et al. BMC Neurology 2012 12:20 doi:10.1186/1471-2377-12-20